Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
Clin ObesSep 6, 2026
Giovanna Pagani Paccola, Roberta Fernandes de Oliveira, Matheus Menão Mochetti et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis compared the efficacy and safety of tirzepatide versus semaglutide for weight loss in adults with overweight or obesity. Analyzing data from 10 studies with 41,381 participants, tirzepatide demonstrated a greater percentage weight reduction than semaglutide, with a mean difference of -4.28 percentage points (95% CI -5.28 to -3.28; p < 0.00001).
Key findings
- Tirzepatide resulted in a greater percentage weight reduction than semaglutide, with a mean difference of -4.28 percentage points.
- Absolute weight loss was also greater with tirzepatide, showing a mean difference of -4.43 kg.
- Tirzepatide had a higher likelihood of achieving weight loss thresholds of ≥10%, ≥15%, and ≥20%.
- Serious adverse events were more frequent with tirzepatide, with a relative risk of 1.83.
Why it matters
Understanding the comparative efficacy of tirzepatide and semaglutide is crucial for clinicians managing patients with overweight or obesity, as it informs treatment decisions and potential outcomes related to weight loss and glycemic control.